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Summary 
 
Neurodevelopmental disorders such as Attention Deficit Hyperactivity Disorder (ADHD) and 
Autism Spectrum Disorder (ASD), although most commonly considered in childhood, can be 
life-long conditions. In this personal perspective that is shaped by clinical experience as well 
as research, we adopt a conceptual approach. First we discuss what disorders are 
neurodevelopmental and why such a grouping is useful. We conclude that both distinction 
and grouping are helpful and that it is important to take into account the strong overlap 
across neurodevelopmental disorders. Then, we highlight some challenges in bridging 
research and clinical practice. We discuss the complexity of clinical phenotypes, the 
importance of the social context and consider developmental change across the life-span. 
Finally we argue the importance of viewing neurodevelopmental disorders as traits but 
highlight that this is not the only approach to use. Overall, we argue strongly for a flexible 
approach in clinical practice that takes into consideration the high level of heterogeneity 
and overlap in neurodevelopmental disorders and for research to link more closely to what 
is observed in real-life practice.  
  
 
 
3 
Search strategy and selection criteria 
This article is a personal perspective and not a review; the authors identified papers according 
to their relevance to the conceptual issues being discussed. Papers published were first 
identified by searches of PubMed from 1st January 2010 to 31st March 2016 using the search 
terms “ADHD”, “autism”, “ASD”, “communication”, “language“, “reading”, “spelling”, “tics” 
AND “child”, “adult”, “longitudinal”, “comorbidity”, “multimorbidity”, “genetic”, “prenatal”, 
“aetiology”. Only articles published in English were included.    Reviews on 
neurodevelopmental disorders, book chapters and NICE guidelines published between 1st 
January 2012 and 2016 and some older articles were also examined. Systematic reviews on 
ADHD and autism are published elsewhere.  
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Neurodevelopmental disorders are complex conditions that are far from straightforward to 
conceptualise.  In this personal perspective article, we discuss some key issues for clinicians 
and scientists to consider. Our views have been shaped by clinical practice as well as by 
research and the intention of this article is to offer our perspective on neurodevelopmental 
disorders.  
What we mean by neurodevelopmental disorder 
The term ‘neurodevelopmental’ has been applied to a very broad group of disabilities 
involving some form of disruption to brain development. This definition groups together a 
very wide range of neurological and psychiatric problems that are clinically and 
aetiologically disparate; for example, rare genetic syndromes, cerebral palsy, congenital 
neural anomalies, schizophrenia, autism, attention deficit hyperactivity disorder (ADHD) and 
epilepsy. In our view, whilst it is important to recognise the importance of early and life-long 
developmental processes for health problems, an overly broad approach to grouping 
neurodevelopmental disorders becomes unhelpful1,2.  
In this article, we adopt the approach of DSM-53 that groups ADHD, Autism Spectrum 
Disorder (ASD), Intellectual Disability, Communication Disorders, Specific Learning Disorders 
and Motor Disorders (e.g. developmental co-ordination disorder and tic disorders) as 
“Neurodevelopmental Disorders” . Whilst we are not enthusiastic about all aspects of DSM-
5, as discussed previously4 this approach to grouping neurodevelopmental disorders is a 
useful one for a variety of reasons2.  
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Why group neurodevelopmental disorders?   
What is the rationale for such a grouping? 
One of the key defining characteristics of these neurodevelopmental disorders is that they 
typically onset in childhood, prior to puberty.  They are also distinguished from many 
neuropsychiatric disorders in respect to their clinical course: despite being subject to 
maturational changes, neurodevelopmental disorders such as ADHD, ASD, intellectual 
disability, learning and communication disorders tend to show a steady course rather than 
the remitting and relapsing pattern that commonly characterises post-pubertal mood 
disorders and schizophrenia. These disorders are also characterised by prominent early-
onset neurocognitive deficits and they more commonly affect males5. Although highly 
heritable6, neurodevelopmental disorders are typically multi-factorial in origin; single major 
causes are rare (e.g. foetal alcohol syndrome, genetic syndromes) and such forms of 
disorder are classified elsewhere2. Finally, the level of overlap between these disorders and 
their constituent symptom dimensions is very high. This further supports the rationale for 
considering them together. As is true of all classification systems and diagnostic groupings, 
neurodevelopmental disorders are highly heterogeneous in terms of their clinical 
characteristics, aetiology, treatment response and outcomes; and there is no specific clinical 
or biological characteristic that clearly distinguishes this grouping from other 
neuropsychiatric disorders. For example, tic disorders do not tend to show a steady course 
and ADHD can remit in some. Schizophrenia and early-onset conduct disorder are 
commonly characterised by early cognitive and developmental impairments but are 
grouped elsewhere in DSM 5 (see elsewhere2 for further discussion of these points). 
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Nevertheless, the early age of onset and high level of overlap means that grouping 
neurodevelopmental disorders in this way is also clinically useful. Assessment and treatment 
expertise for children with these disorders crosses disciplines (e.g. child psychiatrist, 
psychologist, paediatrician, speech and language therapist, occupational therapist) as well 
as agencies (e.g. health and education) and can be fragmented (Figure 1). To provide one 
example, in the UK  a child typically requires assessment for ADHD in a child mental health 
or paediatric service; co-occuring reading disability is the domain of education services, 
motor co-ordination problems need to be assessed by an occupational therapist and 
language/social communications difficulties are the specialist domain of speech and 
language therapists.  Many of these professionals are based in different services and local 
assessment and treatment provision are organised around a single diagnosis (e.g. ADHD or 
ASD7) in a number of countries. If co-occurrence of neurodevelopmental disorders is the 
rule rather than the exception in clinical practice2, then grouping professional expertise, 
services and resources for children with these problems as part of a neurodevelopmental 
hub of expertise can help ensure assessment and intervention across all 
neurodevelopmental domains and explicitly recognise the overlaps.  
Why it is important to retain diagnostic distinctions  
Although grouping is useful, it remains necessary to recognise important distinctions 
between different neurodevelopmental disorders. For example, the differential effects of 
medication highlight that despite overlaps, neurodevelopmental disorders are not 
biologically or clinically identical sets of problems. While stimulant medication8 and 
atomoxetine9 alleviate symptoms of ADHD and atypical antipsychotics can reduce severe 
tics10, none of these medications impact on core features of the other neurodevelopmental 
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disorders. Distinct diagnostic categories, also provide a means for clinicians to readily 
communicate patients’ difficulties with each other and with patients themselves. Thus there 
is a clear indication to retain the practice of distinguishing these disorders as well as 
grouping them. 
 
Neurodevelopmental disorders are more than their defining symptoms  
Disaggregating individual clinical profiles  
Historical tradition has influenced the defining features of many neurodevelopmental 
disorders and some of the decisions as to what to include might be considered arbitrary. 
Phenotypically, neurodevelopmental disorders are more than a defining set of symptoms 
and extend beyond the boundaries of a neurodevelopmental group. Indeed Kanner, in his 
1969 article on differential diagnosis 11, highlighted the tendency to pigeonhole patients into 
a category rather than really understand them - “that children had not read the right books” 
when it came to diagnosis. If we take ADHD as the example here, relevant, common ADHD 
profiles (see Figure 21) include not only its defining symptoms (hyperactive-impulsiveness, 
inattention) and features of other neurodevelopmental disorders but also additional 
cognitive deficits such as impaired working memory and planning12,13. Equally, emotional 
features involving mood lability and irritability used to be considered an integral aspect of 
ADHD14 but would now be considered as part of a co-occurring disorder (e.g. anxiety, 
depression or oppositional defiant disorder). The overlap of ADHD with conduct problems is 
also prominent15. Some of these symptom profiles will be recognised as an additional 
diagnosis. However if symptoms do not achieve the threshold for a diagnosis, they will not 
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be captured for the purpose of either research or clinical practice; the clinical implications of 
sub-threshold symptoms will be discussed later in this article.  
The same historical tradition has influenced diagnostic exclusion criteria. For example, it has 
long been appreciated that the autistic spectrum includes children with intellectual 
disability, but in the case of ADHD, the absence of intellectual disability (ID) was highlighted 
as important16. However, this assumption is now recognised to be invalid, and the practice 
of failing to diagnose ADHD in the presence of ID is starting to change17,18.   
The finding that those exposed to early, severe privation display features of “quasi-
autism”19 provides an illustrative case of how disorders may present in an unusual fashion in 
an atypical social context. This highlights the importance of why assessments of 
phenomenology need to extend beyond core diagnostic criteria and the constraints of a 
structured interview. However in clinical settings, assessments will typically extend beyond 
diagnostic items and most would accept the importance of assessing social context and 
taking into account an individual’s current “resources” (e.g. cognitive ability, quality of 
parenting, income) and “demands” (e.g. classroom environment), as well as their level of 
functioning, in order to devise a comprehensive management plan.  
How patterns of multiple symptom and contextual profiles are captured for research 
purposes is a relevant challenge if Ggaps between research and clinical practice needare to 
be bridged. Our view is that observation and clinical insights remain valuable for informing 
research questions. Also, and that research participants need to be characterised beyond a 
single core diagnosis; for example by assessing participants across multiple dimensions of 
symptoms, functioning and social contexts, regardless of primary diagnosis. A shared 
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measurement tool kit used by different health-care professionals and researchers might be 
helpful here. 
 
Why are profiles beyond core diagnostic features relevant? 
Selecting appropriate treatments: First, for clinicians, different problem areas may require 
different sorts of evidence-based treatments that would not be captured by treatment 
guidelines for a single neurodevelopmental disorder; for example cognitive behavioural 
strategies (CBT) for anxiety20 and parenting interventions for behaviour problems21. 
Secondly, an individual’s symptom profile across multiple dimensions can provide a useful 
prognostic index.  Co-occurrence rates of problems and disorders are elevated in clinics - so 
called Berkson’s bias. This selection is unsurprising given that those with problems in 
multiple disorder domains are more severely impaired in terms of outcomes22. 
Predicting outcomes: What sorts of co-occurring problems index a poorer outcome? One 
possibility is that it is the consequence of the total burden of childhood problems regardless 
of the nature of psychopathology. Recent work by Copeland and colleagues 23 addresseds 
this using the Great Smoky Mountains longitudinal study of child psychopathology. These 
investigators found that the cumulative childhood burden of psychopathology was the best 
predictor of adult health (e.g. addictions, suicidality, serious physical illness), legal (e.g. 
criminal act), financial (e.g. unable to keep job) and social outcomes (e.g. no social support), 
even allowing for adult psychopathology and childhood psychosocial adversity. In a more 
recent UK population-based study, the total childhood burden of neurodevelopmental and 
conduct problems predicted a persistent ADHD symptom trajectory to adolescence. The Formatted: Highlight
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mechanisms by which cumulative childhood mental health burden leads to poor outcomes 
require investigation.  
Other evidence highlights that different symptom profiles show specificity in relation to the 
type of later psychopathology and functional outcome24,25. For example, in a Swedish study 
of multiple neurodevelopmental problems26 childhood ADHD predicted adolescent 
antisocial behaviour and impaired functioning independent of other neurodevelopmental 
problems. A systematic review of longitudinal ASD studies, highlighted that child IQ and 
early language ability appear to be the strongest predictors of ASD outcome27. The degree 
to which later functional and psychiatric outcomes of neurodevelopmental disorders are 
predicted by specific symptom profiles and/or the total burden of problems needs further 
investigation, as do the biological/social mechanisms that explain variation in outcomes. 
Longitudinal studies that span from childhood to adult-life are required to address such 
questions.  
Multi-morbidity in clinical practice 
The concept of multi-morbidity in physical medicine acknowledges the clinical importance of 
multiple problems in a single individual. Multi-morbidity is commonly defined as the 
presence of two or more chronic conditions in the same individual and is now a major 
concern in general medicine/primary care. That is because of growing recognition that 
multi-morbidity is common and has important clinical and service implications (Barnett et al, 
2012) (https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0704).  
 Fragmented service provision is one problem for patients with multi-morbidity. Clinical 
pathways which focus explicitly on the diagnostic process of one condition alone may be 
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missing salient features of other disorders. Another is that assessment and treatment 
guidelines, including those relevant for ADHD and ASD7,28  typically focus on a single 
disorder, yet treatment needs as well as prognosis might be altered in the presence of other 
disorders.  
How might treatment be affected? First, the threshold for treating one condition might be 
altered by the presence of other conditions (e.g. in the presence of certain conditions 
including renal disease and diabetes, the threshold for treating hypertension is lower)29. 
Second, the effectiveness of a recommended treatment for the primary condition might be 
moderated by the presence of other conditions. This has not been widely investigated for 
child psychopathology although there are some exceptions20,30. For example, in the case of 
ADHD, behavioural interventions appear to be especially helpful for those with anxiety30 and 
although stimulants reduce ADHD symptoms in those with intellectual disability or ASD, 
medication is less well-tolerated 31,32. At present, we have limited evidence on how clinical 
management might be altered in the context of neurodevelopmental multi-morbidity; for 
example should the threshold for providing intervention for communication impairments or 
ASD be lowered in the presence of ADHD? Typically, the diagnostic process is hierarchical 
and parsimonious and sometimes that is helpful because it simplifies the key issues and can 
help focus on the predominant features. However it is being increasingly recognised that 
using a hierarchical approach and exclusion criteria can be problematic because important 
features beyond the diagnosis of primary interest might not be assessed and treated or 
considered in research studies; for example, prior to DSM-5, ADHD could not be diagnosed 
in the presence of ASD33. This has meant that many research studies did not assess both 
phenotypes or excluded those with both conditions until this notion began to be 
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challenged34. Future intervention and outcome research on individuals with multiple 
neurodevelopmental problems would be helpful in addressing this knowledge gap. 
 
 
 
 
Neurodevelopmental disorders conceptualised as traits 
Evidence that neurodevelopmental disorders behave as traits  
There is strong research evidence that favours considering some neurodevelopmental 
disorders/diagnoses as lying at the extremes of dimensions13,35,36.  For example,  ADHD 
defined as a trait, typically using total symptom scores, behaves dimensionally in terms of its 
relationship with adverse outcomes 37 - there is no clear-cut threshold beyond which 
adverse outcomes emerge. Also, the same genetic and early environmental risk factors that 
are associated with a diagnosis of ADHD or ASD predict  trait levels in the general population 
38–42.  However categorical conceptualisation can be helpful for some purposes4; for 
example when dichotomous and potentially risky clinical decisions, such as whether to 
prescribe medication for a child or not, have to be made.  
Where does the cut-point on a dimension lie?  
This question is not straightforward to address because it depends on what the cut-point is 
required for. In general for child psychopathology, sub-threshold diagnoses (fewer 
symptoms but impairment) are common and are clinically important in terms of predicting 
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poorer adult mental health and function outcomes23. However expanding diagnoses is 
unhelpful because there are potential social, psychological and health risks 43 as well as 
benefits of applying a diagnostic label and providing treatments.  For example, NICE 
guidance for ADHD28 applies a lower threshold for psychosocial intervention than for 
medication and recommends a step-wise treatment approach13 but that does not deal with 
the public health issue of sub-threshold cases of any neurodevelopmental disorder.  
What is the dimension?  
Another question is how should one define the underlying dimension given a diagnosis is 
more than just one trait? For example, ADHD symptom scores are highly correlated with 
many other traits, so a diagnosis of ADHD might not even be best conceptualised as lying at 
the extreme of a single measured ADHD trait (i.e. total ADHD symptom count) but rather as 
being underpinned by multiple trait as well as biological liabilities44,45. 
Alternatives to a traditional categorical diagnostic approach are being considered in the 
context of research. The Research Domain Criteria (R-DoC) project is one such research 
framework proposed by the NIMH 46. It has been proposed as a means of investigating 
mental disorders by conceptualising them as dimensional constructs (e.g. negative valence 
systems) (http://www.nimh.nih.gov/research-priorities/rdoc/constructs/rdoc-matrix.shtml) 
which transcend diagnostic categories and  integrate information across multiple 
measurement levels (e.g. genes, molecules, cells, circuits as well as self-reports). Whilst a 
dimensional framework is to be welcomed, and will be helpful for some types of research 
e.g. bridging basic science and human cognitive and imaging research47, as yet we do not 
have reliable methods for assessing many of the suggested R-doc dimensions and nor do we 
know how they map onto complex, clinically relevant problems. There are some examples of 
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research that links biology to clinical phenomena; for example, longitudinal imaging studies 
suggest that ADHD persistence versus remission is associated with brain maturation45. It is 
important that this gap is spanned if research is going to inform clinical practice and clinical 
observations are to inform basic research. One challenge will be to avoid an oversimplified 
view of psychopathology that fails to recognise the importance of social factors and 
developmental change.  
 
Consideration of developmental change and a life-span approach 
Symptom decline but persistence to adult life  
Neurodevelopmental disorders are subject to maturational change2. Many child 
neurodevelopmental disorders typically improve with age and previously were considered 
as childhood-limited problems. However, follow-up studies show that although outcomes 
are variable, for many individuals, neurodevelopmental problems/diagnosis do persist into 
adult life 1,48–52. Reported estimates of diagnostic persistence rates vary widely and tend to 
be higher in patient samples than in population-based cohorts53. For example, if we take the 
example of ADHD, one meta-analysis suggested a 15% ADHD diagnostic persistence rate to 
adult life 48. ASD, language impairments54 and literacy-related55 difficulties also commonly 
persist in many. Some core symptoms, for example ADHD-related hyperactive-
impulsiveness56, and ASD-related behaviours27, decline considerably with age. In recognition 
of this the required number of ADHD symptoms for a DSM-5 diagnosis of ADHD has been 
adjusted for adolescents and adults.  However service provision for neurodevelopmental 
disorders in adult life is limited57,58.  
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Change in predominant manifestation  
Change does not simply involve a decline in core symptoms as the predominant clinical 
manifestations are also subject to change and new co-occurring problems (e.g. substance 
misuse) can emerge 59. For example, many who do not meet full diagnostic criteria for ADHD 
or ASD in adult life have sub-threshold persistence of core symptoms and a broader range of 
cognitive, psychiatric (e.g. mood disorder, substance misuse) and functional impairments 
such as difficulties with employment or social relationships 53,59,60. At present, there is very 
little known about potentially modifiable factors (e.g. prenatal and early life environmental 
enrichment, social influences) that optimise neurodevelopmental outcomes and this is an 
important area for future research. Longitudinal observational designs will remain 
important but other methods then are required to test causal hypotheses (as discussed 
extensively elsewhere61). 
A life-course view 
Until recently, it has been assumed that adult symptoms of neurodevelopmental disorders 
must be a continuation from childhood-onset problems. However an intriguing recent 
finding from the Dunedin longitudinal cohort group challenges this assumption in relation to 
ADHD. Moffitt and colleagues 53 found that most cases of adult ADHD at age 38 years were 
not preceded by a childhood diagnosis. This finding has been replicated now in two 
independent adolescent/young adult samples62,63. The problems were not entirely explained 
by concurrent or earlier comorbidities. The explanation of this phenomenon being explained 
by sub-threshold cases is also unsatisfactory. The findings raise the question of what this 
adult ADHD phenotype is. Is it the manifestation of symptoms suppressed earlier in life due 
to early protective factors or does it represent a different disorder altogether with a 
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different pathogenesis akin to juvenile-onset and maturity-onset diabetes? These findings 
have important implications for adult mental health services as well as for future research64. 
There is a need for detailed longitudinal characterisation of neurodevelopmental disorder 
phenotypes across ages in unselected populations to examine patterns of onset, desistence 
and persistence across the life-span. One challenge for such developmentally informative 
research is that both researchers and clinicians use different measures after age 16-18 years 
and informants typically change from parent- to self-reports in adult life. One approach that 
might help bridge this gap between childhood and adult life is to encourage research 
investigations (and clinical services) that focus on transition ages (e.g. ages 15 to 25 years).  
 
Perspectives on how clinicians and researchers might proceed 
Adopt a conceptual approach  
Our main conclusion is that regardless of what framework is used for conceptualising 
neurodevelopmental or psychiatric disorders, there are problems if clinicians and 
researchers apply them rigidly without thought or critical reflection; for example by 
counting up items generated by a structured interview or generating a score (e.g. ADI and 
ADOS generated diagnosis of ASD). Thresholds for defining disorders, that is the numbers of 
required symptoms, are arbritary. Failing to recognising comorbidities or symptoms beyond 
the primary diagnosis of interest is another risk. Historically such an approach has caused 
problems (for example, comorbid ADHD and ASD being disallowed by DSM and ICD) for 
researchers and clinical practitioners. For example, a child might not meet the exact 
symptom cut-point for a diagnosis of ADHD but if they fall just below the diagnostic 
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threshold and symptoms are interfering with functioning-then behavioural and social 
approaches typically used for ADHD might be helpful.  
It is also important to adopt a developmental view across the life-span regardless of age 
and; this requires longitudinal research approaches that bridge child and adult life  and a 
clinical perspective that goes beyond current presenting problems. consider the history of 
the disorder in an individual patient and prognostic indicators with regards to future 
treatment planning and service provision across the life-span. The clinician is required to 
weigh up multiple factors when conducting assessments, planning intervention and 
predicting outcomes (see Leckman & Taylor for details of a “common-sense approach”). 
Individuals with the same diagnosis might require very different types of intervention 
depending on co-occuring symptoms, age (e.g. an adult vs. prepubertal child), social context 
(e.g. low income single parent with mental health problems and limited support at school 
vs. high income, strongly supportive extended family, private tutoring in addition to school).  
Consider complexity vs. reductionism  
We conclude that it is clinically helpful and scientifically justified to group 
neurodevelopmental disorders but necessary also to retain diagnostic distinctions. Of 
course, we recognised there is enormous heterogeneity in symptoms, outcome and 
treatment response across all neurodevelopmental and psychiatric disorders and there are 
no clear-cut boundaries between different disorders or between different groups of 
disorders. The strong overlap and a lack of clear-water between disorders does not mean it 
is necessarily helpful to completely dispense with diagnostic boundaries or groupings. Most 
clinicians will recognise that neurodevelopmental disorders are more than a set of 
diagnostic criteria and that multiple impairments or multi-morbidity are the rule rather than 
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exception. However research funders, service funding and planning, local assessment 
policies and national guidelines are not necessarily as flexible.  Interventions are not 
identical for different types of problems so it is important to capture these complex 
phenotype patterns and associated subthreshold symptoms, and consider the social context 
and developmental factors in research as well as clinical practice. This is achievable and 
there are many examples of such research, some of which we have already discussed23,65. 
Complexity is the nature of clinical problems, so perhaps it is better to acknowledge this and 
attempt its capture if the gaps between neuroscience and mental health research as well as 
between research and real-life clinical practice are ever to be bridged. Clinicians need to 
apply clinical judgement as well as evidence and guidelines and researchers need to engage 
directly with clinicians so that research is clinically meaningful.  
A neurodevelopmental disorder diagnosis is inadequate as a means of "rationing"  
In our view, as patient expectations grow and resources diminish66, clinicians are being 
called upon to make decisions that affect resource allocation for a patient. It is not 
reasonable for services or agencies however to allocate intervention and support purely on 
the basis of a yes/no diagnosis, including ones made after lengthy, protracted and expensive 
assessments (e.g. educational support to be linked to a diagnosis of ASD). That is because an 
individual's needs are not best captured by diagnosis alone. Systematic and validated 
methods for assessing the needs of children and adults with neurodevelopmental disorders 
beyond diagnosis are needed to avoid those with subthreshold symptomatology but 
significant impairment missing out on vital service provision.  
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So do we dispense with diagnosis? We think not. There are long-standing arguments in 
psychiatry disputing the validity and value of diagnosis and on lumping vs. splitting different 
forms of psychopathology as well as concerns and apologies about relying on reported 
symptoms. This is not helpful for practitioners and patients. 
For current purposes they are reasonably reliable, useful for communication and attempting 
to standardise treatment approaches provided they are used sensibly as a framework (see 
Table 12), rather than as fundamental truths; and not as the sole means of determining 
patient care.  For researchers, it is premature in our view to dispense with diagnoses but 
equally we need to empirically and critically assess the value of alternatives. 
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Table 1: Conceptualising neurodevelopmental disorders: a summary 
 
 Group and distinguish neurodevelopmental disorders 
 
 Disaggregate beyond core diagnostic symptoms 
 Consider overall burden of psychopathology /multi-morbidity 
 
 Social context (demands, resources and risks) is important 
 
 Take into account developmental change across the life-span and maturational influences 
 
 Traits and categorical diagnoses are useful 
 
 Unhelpful to dispense with diagnosis or rigidly adhere to them 
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Agencies that might be involved in assessment, 
treatment and follow-up 
Education                        Primary care                 Social care/voluntary 
sector 
 
 
 
Speech and Language Occupational therapy,  
Therapy     Physiotherapy 
Mental Health           Child Health 
 
 
 
Figure 1. Assessment and management of neurodevelopmental problems: the potential for 
fragmentation of services 
Presenting manifestation 
Scholastic 
Behavioural 
Emotional 
Social 
Communication 
Motor 
Social/family adversity and 
stress 
Physical health e.g. 
seizures 
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Figure 1 
 
Common clinical profiles associated with ADHD: where disaggregating a single diagnosis can be 
helpful 
 
 
 
 
 
 
 
 
 
 
 
   
  
  
 
Example 1: A child with ADHD and no other diagnosis could present with language and motor 
difficulties, executive dysfunction that further adversely impact on daily life and educational 
performance. The predominant concern of the family might be to do with severe, uncontrollable 
angry outbursts (irritability) that disrupt family relationships. All these domains are relevant for 
assessment and intervention. The effectiveness of simultaneous interventions for the total profile of 
difficulties that accompany the primary diagnosis, even if these do not reach the required threshold 
for a “comorbid diagnosis”, needs scientific evaluation. 
  
Core ADHD symptoms that contribute to 
primary diagnosis 
Hyperactivity 
Impulsiveness 
Inattention 
Neurodevelopmental 
problems 
e.g. social communication, 
language, motor  
Cognitive impairments 
e.g. executive function, 
response inhibition 
Emotional  
e.g. emotional lability, irritability, 
anxiety 
 
links with later depression 
Behavioural 
e.g. aggression, headstrong/hurtful 
 
links with later antisocial behaviour 
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Five research questions 
 Using longitudinal patient and population-based cohort designs, wWhat potentially 
modifiable factors optimise neurodevelopmental outcomes? Test causal effects through 
different research approaches (e.g. quasi-experimental and animal studies). 
 How does multi-morbidity affect neurodevelopmental outcomes and the threshold for 
treatment (e.g. longitudinal observational studies, treatment trials of complex patients)? 
 What is the natural history of neurodevelopmental disorders in the general population 
across ages (e.g. via longitudinal population cohort designs)? 
 How does social context (within and across countries) contribute to neurodevelopmental 
disorder associated impairments? For example, do longer-term outcomes and impairments 
differ across time and populations? This could be achieved by investigating outcomes in low 
and middle-income vs. high-income countries, for example. 
 Can we identify neurodevelopmental disorder subtypes that are clinically useful and that 
might transcend diagnostic boundaries and (e.g. predict functional outcomes)? 
 
 
 
 
 
  
  
 
 
24 
References 
1 Rutter M, Kim-Cohen J, Maughan B. Continuities and discontinuities in psychopathology 
between childhood and adult life. J Child Psychol Psychiatry Allied Discip 2006; 47: 276–95. 
2 Thapar A, Rutter M. Neurodevelopmentmental Disorders. Rutter’s Child Adolesc Psychiatry 
2015; : 31–40. 
3 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th 
edn. Washington, 2013. 
4 Rutter M. Research review: Child psychiatric diagnosis and classification: concepts, findings, 
challenges and potential. J Child Psychol Psychiatry 2011; 52: 647–60. 
5 Rutter M, Caspi A, Moffitt TE. Using sex differences in psychopathology to study causal 
mechanisms: unifying issues and research strategies. J Child Psychol Psychiatry 2003; 44: 
1092–115. 
6 Lichtenstein P, Carlström E, Råstam M, Gillberg C, Anckarsäter H. The genetics of autism 
spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry 
2010; 167: 1357–63. 
7 Autism | Guidance and guidelines | NICE. . 
8 A 14-month randomized clinical trial of treatment strategies for attention-
deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of 
Children with ADHD. Arch Gen Psychiatry 1999; 56: 1073–86. 
9 Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent 
attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. J 
Psychopharmacol 2014; 28: 204–11. 
10 Leckman JF, Bloch MH. Tic Disorders. In: Thapar A, Pine DS, Leckman JF, Scott S, Snowling MJ, 
Taylor EA, eds. Rutter’s Child and Adolescent Psychiatry, 6th edn. Chichester: Wiley-
Blackwell, 2015: 757–73. 
11 Kanner L. The children haven’t read those books, reflections on differential diagnosis. Acta 
Paedopsychiatr 1969; 36: 2–11. 
12 Willcutt EG, Doyle AE, Nigg JT, Faraone S V, Pennington BF. Validity of the executive function 
theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry 
2005; 57: 1336–46. 
13 Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet (London, England) 2015; 
published online Sept 16. DOI:10.1016/S0140-6736(15)00238-X. 
14 Shaw P, Stringaris A, Nigg J, Leibenluft E. Emotion dysregulation in attention deficit 
hyperactivity disorder. Am J Psychiatry 2014; 171: 276–93. 
15 Thapar A, van den Bree M, Fowler T, Langley K, Whittinger N. Predictors of antisocial 
behaviour in children with attention deficit hyperactivity disorder. Eur Child Adolesc 
Psychiatry 2006; 15: 118–25. 
16 Still G. Some abnormal psychical conditions in children: the Goulstonian lectures. Lancet 
 
 
25 
1902; 1: 1008–12. 
17 Simonoff E, Taylor E, Baird G, et al. Randomized controlled double-blind trial of optimal dose 
methylphenidate in children and adolescents with severe attention deficit hyperactivity 
disorder and intellectual disability. J Child Psychol Psychiatry 2013; 54: 527–35. 
18 Ahuja A, Martin J, Langley K, Thapar A. Intellectual disability in children with attention deficit 
hyperactivity disorder. J Pediatr 2013; 163: 890–5.e1. 
19 Kreppner JM, O’Connor TG, Rutter M. Can inattention/overactivity be an institutional 
deprivation syndrome? J Abnorm Child Psychol 2001; 29: 513–28. 
20 Weisz JR, Ng MY, Lau N. Psychological interventions: Overview and critical issues for the field. 
In: Thapar A, Pine DS, Leckman JF, Scott S, Snowling MJ, Taylor EA, eds. Rutter’s Child and 
Adolescent Psychiatry: Sixth Edition, 6th edn. Chichester: Wiley-Blackwell, 2015: 461–82. 
21 Scott S. Oppositional and Conduct Disorders. In: Thapar A, Pine DS, Leckman JF, Scott S, 
Snowling M, Taylor E, eds. Rutter’s Child and Adolescent Psychiatry, 6th edn. Oxford: John 
Wiley & Sons Limited, 2015: 913–30. 
22 Caye A, Spadini A V, Karam RG, et al. Predictors of persistence of ADHD into adulthood: a 
systematic review of the literature and meta-analysis. Eur Child Adolesc Psychiatry 2016; 
published online March 28. DOI:10.1007/s00787-016-0831-8. 
23 Copeland WE, Wolke D, Shanahan L, Costello EJ. Adult Functional Outcomes of Common 
Childhood Psychiatric Problems: A Prospective, Longitudinal Study. JAMA psychiatry 2015; 72: 
892–9. 
24 Cuffe SP, Visser SN, Holbrook JR, et al. ADHD and Psychiatric Comorbidity: Functional 
Outcomes in a School-Based Sample of Children. J Atten Disord 2015; published online Nov 
25. DOI:10.1177/1087054715613437. 
25 Fergusson DM, Lynskey MT, Horwood LJ. Attentional difficulties in middle childhood and 
psychosocial outcomes in young adulthood. J Child Psychol Psychiatry 1997; 38: 633–44. 
26 Norén Selinus E, Molero Y, Lichtenstein P, et al. Childhood Symptoms of ADHD Overrule 
Comorbidity in Relation to Psychosocial Outcome at Age 15: A Longitudinal Study. PLoS One 
2015; 10: e0137475. 
27 Magiati I, Tay XW, Howlin P. Cognitive, language, social and behavioural outcomes in adults 
with autism spectrum disorders: a systematic review of longitudinal follow-up studies in 
adulthood. Clin Psychol Rev 2014; 34: 73–86. 
28 National Institute for Health and Clinical Excellence (Nice). NICE clinical guideline 72: 
Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, 
young people and adults. 2013 http://www.nice.org.uk/guidance/cg72. 
29 Hypertension in adults: diagnosis and management  | Guidance and guidelines | NICE. . 
30 Ollendick TH, Jarrett MA, Grills-Taquechel AE, Hovey LD, Wolff JC. Comorbidity as a predictor 
and moderator of treatment outcome in youth with anxiety, affective, attention 
deficit/hyperactivity disorder, and oppositional/conduct disorders. Clin Psychol Rev 2008; 28: 
1447–71. 
31 Simonoff E, Taylor E, Baird G, et al. Randomized controlled double-blind trial of optimal dose 
 
 
26 
methylphenidate in children and adolescents with severe attention deficit hyperactivity 
disorder and intellectual disability. J Child Psychol Psychiatry 2013; 54: 527–35. 
32 Reichow B, Volkmar FR, Bloch MH. Systematic review and meta-analysis of pharmacological 
treatment of the symptoms of attention-deficit/hyperactivity disorder in children with 
pervasive developmental disorders. J Autism Dev Disord 2013; 43: 2435–41. 
33 American Psychiatric Association. Diagnostic and Statistical Manual of mental disorders, 4th 
edition. Washington, 1994. 
34 Rommelse NNJ, Altink ME, Fliers E a, et al. Comorbid problems in ADHD: degree of 
association, shared endophenotypes, and formation of distinct subtypes. Implications for a 
future DSM. J Abnorm Child Psychol 2009; 37: 793–804. 
35 Norbury CF. Practitioner review: Social (pragmatic) communication disorder 
conceptualization, evidence and clinical implications. J Child Psychol Psychiatry 2014; 55: 
204–16. 
36 Rutter M. Changing concepts and findings on autism. J Autism Dev Disord 2013; 43: 1749–57. 
37 Bussing R, Mason DM, Bell L, Porter P, Garvan C. Adolescent outcomes of childhood 
attention-deficit/hyperactivity disorder in a diverse community sample. J Am Acad Child 
Adolesc Psychiatry 2010; 49: 595–605. 
38 Levy F, Hay DA, McStephen M, Wood C, Waldman I. Attention-deficit hyperactivity disorder: a 
category or a continuum? Genetic analysis of a large-scale twin study. J Am Acad Child 
Adolesc Psychiatry 1997; 36: 737–44. 
39 Martin J, Hamshere ML, Stergiakouli E, O’Donovan MC, Thapar A. Genetic risk for attention-
deficit/hyperactivity disorder contributes to neurodevelopmental traits in the general 
population. Biol Psychiatry 2014; 76: 664–71. 
40 Stergiakouli E, Martin J, Hamshere ML, et al. Shared Genetic Influences Between Attention-
Deficit/Hyperactivity Disorder (ADHD) Traits in Children and Clinical ADHD. J Am Acad Child 
Adolesc Psychiatry 2015; 54: 322–7. 
41 Robinson EB, St Pourcain B, Anttila V, et al. Genetic risk for autism spectrum disorders and 
neuropsychiatric variation in the general population. Nat Genet 2016; 48: 552–5. 
42 Mandy W, Lai M-C. Annual Research Review: The role of the environment in the 
developmental psychopathology of autism spectrum condition. J Child Psychol Psychiatry 
2016; 57: 271–92. 
43 Craddock N, Mynors-Wallis L, Gornall J, et al. Psychiatric diagnosis: impersonal, imperfect and 
important. Br J Psychiatry 2014; 204: 93–5. 
44 Martin J, Hamshere ML, Stergiakouli E, O’Donovan MC, Thapar A. Neurocognitive abilities in 
the general population and composite genetic risk scores for attention-deficit hyperactivity 
disorder. J Child Psychol Psychiatry 2015; 56: 648–56. 
45 Shaw P, Malek M, Watson B, Greenstein D, de Rossi P, Sharp W. Trajectories of cerebral 
cortical development in childhood and adolescence and adult attention-deficit/hyperactivity 
disorder. Biol P 2013; 74: 599–606. 
46 Cuthbert BN. Research Domain Criteria: toward future psychiatric nosologies. Dialogues Clin 
 
 
27 
Neurosci 2015; 17: 89–97. 
47 Pine DS. Editorial: Lessons learned on the quest to understand developmental 
psychopathology. J Child Psychol Psychiatry 2010; 51: 533–4. 
48 Faraone S V, Biederman J, Mick E. The age-dependent decline of attention deficit 
hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006; 36: 159–65. 
49 Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-
deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009; 194: 204–11. 
50 Howlin P, Goode S, Hutton J, Rutter M. Adult outcome for children with autism. J Child 
Psychol Psychiatry 2004; 45: 212–29. 
51 Anderson DK, Liang JW, Lord C. Predicting young adult outcome among more and less 
cognitively able individuals with autism spectrum disorders. J Child Psychol Psychiatry 2014; 
55: 485–94. 
52 Magiati I, Tay XW, Howlin P. Cognitive, language, social and behavioural outcomes in adults 
with autism spectrum disorders: a systematic review of longitudinal follow-up studies in 
adulthood. Clin Psychol Rev 2014; 34: 73–86. 
53 Moffitt TE, Houts R, Asherson P, et al. Is Adult ADHD a Childhood-Onset Neurodevelopmental 
Disorder? Evidence From a Four-Decade Longitudinal Cohort Study. Am J Psychiatry 2015; 
172: 967–77. 
54 Whitehouse AJO, Line EA, Watt HJ, Bishop DVM. Qualitative aspects of developmental 
language impairment relate to language and literacy outcome in adulthood. Int J Lang 
Commun Disord; 44: 489–510. 
55 Maughan B, Messer J, Collishaw S, et al. Persistence of literacy problems: spelling in 
adolescence and at mid-life. J Child Psychol Psychiatry 2009; 50: 893–901. 
56 Pingault J-B, Viding E, Galéra C, et al. Genetic and Environmental Influences on the 
Developmental Course of Attention-Deficit/Hyperactivity Disorder Symptoms From Childhood 
to Adolescence. JAMA psychiatry 2015; 72: 651–8. 
57 Hall CL, Newell K, Taylor J, Sayal K, Hollis C. Services for young people with attention 
deficit/hyperactivity disorder transitioning from child to adult mental health services: A 
national survey of mental health trusts in England. J Psychopharmacol 2015; 29: 39–42. 
58 Swift KD, Sayal K, Hollis C. ADHD and transitions to adult mental health services: a scoping 
review. Child Care Health Dev 2014; 40: 775–86. 
59 Klein RG, Mannuzza S, Olazagasti MAR, et al. Clinical and functional outcome of childhood 
attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry 2012; 69: 1295–
303. 
60 Whitehouse AJO, Watt HJ, Line EA, Bishop DVM. Adult psychosocial outcomes of children 
with specific language impairment, pragmatic language impairment and autism. Int J Lang 
Commun Disord; 44: 511–28. 
61 Thapar A, Rutter M. Using natural experiments and animal models to study causal hypotheses 
in relation to child mental health problems. In: Thapar A, Pine DS, Leckman JF, Scott S, 
Snowling M, Tay, eds. Rutter’s Child and Adolescent Psychiatry, 6th edn. Oxford: John Wiley 
 
 
28 
and Sons Limited, 2015: 145–62. 
62 Agnew-Blais JC, Polanczyk G V., Danese A, Wertz J, Moffitt TE, Arseneault L. Evaluation of the 
Persistence, Remission, and Emergence of Attention-Deficit/Hyperactivity Disorder in Young 
Adulthood. JAMA Psychiatry 2016; published online May 18. 
DOI:10.1001/jamapsychiatry.2016.0465. 
63 Caye A, Rocha TB-M, Anselmi L, et al. Attention-Deficit/Hyperactivity Disorder Trajectories 
From Childhood to Young Adulthood: Evidence From a Birth Cohort Supporting a Late-onset 
Syndrome. JAMA psychiatry 2016; published online May 18. 
DOI:10.1001/jamapsychiatry.2016.0383. 
64 Faraone S V, Biederman J. Can Attention-Deficit/Hyperactivity Disorder Onset Occur in 
Adulthood? JAMA psychiatry 2016; published online May 18. 
DOI:10.1001/jamapsychiatry.2016.0400. 
65 Kreppner JM, Rutter M, Beckett C, et al. Normality and impairment following profound early 
institutional deprivation: A longitudinal follow-up into early adolescence. Dev Psychol 2007; 
43: 931–46. 
66 Ham C, Dixon A, Brooke B. Transforming the delivery of health and social care: The case for 
fundamental change. www.kingsfund.org.uk (accessed July 18, 2016). 
  
 
 
